ArticleFrontiers in immunology2026
Comprehensive characterization of SLC41A3 identifies it as an immune-related prognostic biomarker and therapeutic target in hepatocellular carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) represents a highly aggressive cancer associated with substantial patient mortality. Members of the solute carrier (SLC) protein family have been implicated in facilitating tumor development and progression. However, the specific functions and relevance of SLC41A3 in the context of HCC pathogenesis are not well defined. Methods: Differentially expressed SLC genes were screened from the TCGA-LIHC cohort. Prognostic analysis identified independent prognostic factors. Diagnostic and prognostic models were constructed using machine learning and LASSO regression. Multi-omics analysis was employed to assess the expression characteristics, clinical relevance, spatial heterogeneity, and correlation with immune infiltration of SLC41A3. The biological function of SLC41A3 was validated through Results: Sixty-nine SLC genes were differentially expressed in HCC, with eight identified as independent prognostic factors, including SLC41A3. The constructed diagnostic and prognostic models based on these genes demonstrated robust performance. SLC41A3 was highlighted as the most contributory feature in the diagnostic model. High expression of SLC41A3 was significantly associated with advanced clinicopathological features, poorer patient survival, specific spatial expression patterns, and altered immune cell infiltration in the tumor microenvironment. Functionally, knockdown of SLC41A3 significantly inhibited HCC cell proliferation, migration, invasion Conclusion: This study identifies SLC41A3 as a novel prognostic biomarker and a promoter of HCC progression, with its function potentially linked to immune microenvironment modulation, suggesting its promise as a therapeutic target for HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.